Amgen, Amneal Tell Fed. Circ. To Redo Sensipar IP Ruling
Amgen and Amneal have both asked a Federal Circuit panel to reconsider its mixed decision about which proposed generic drugs infringe Amgen's patented medication Sensipar, which is given to kidney disease and cancer patients. ...To view the full article, register now.
Already a subscriber? Click here to view full article